The study, conducted by Public Health England, looked at data on all symptomatic sequenced cases of COVID-19 in England.
It also found that AstraZeneca’s vaccine was 67 percent effective against the delta variant. Both shots were far less effective after only one dose, at around 30 percent effective.
The efficacy against hospitalization and death from the delta variant wasn’t measured in this study.
An Israeli study released earlier this month found Pfizer’s shot was just 64 percent effective against the delta variant, but that study’s method has been criticized by some experts, according to The Hill.
Find the full study here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.